This is a summary of the European public assessment report (EPAR) for Moventig. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Moventig. For practical information about using Moventig, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).
Therapeutic Area (MeSH)
N/AATC Code
A06AH03
ATC Item
naloxegol
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| naloxegol oxalate | N/A | 纳洛醇醚 |
EMA Name
Moventig
Medicine Name
Moventig
Aliases
N/ANo risk management plan link.
